

AFFYMAX INC
Form 8-K
November 05, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **November 1, 2007**

AFFYMAX, INC.

(Exact name of registrant as specified in charter)

Delaware
(State or other jurisdiction of
incorporation)

001-33213
(Commission File Number)

77-0579396
(I.R.S. Employer Identification No.)

4001 Miranda Avenue
Palo Alto, California 94304

(Address of principal executive offices and zip code)

Edgar Filing: AFFYMAX INC - Form 8-K

Registrant's telephone number, including area code: **(650) 812 -8700**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On November 1, 2007, Affymax, Inc. (the Company) issued a press release announcing that Robert B. Naso, Ph.D., the Company's Executive Vice President of Research and Development, plans to retire at the end of 2007. The Company plans to retain Dr. Naso as a consultant to advise on the strategic management of the Company. Dr. Naso's direct reports, including Anne-Marie Duliege, M.D., M.S., Chief Medical Officer, Robert F. Venteicher, Ph.D., Vice President, Technical Operations and Peter R. Young, Ph.D., Vice President, Research, will report directly to Arlene M. Morris, President and Chief Executive Officer of the Company upon Dr. Naso's retirement.

The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statement and Exhibits.

(d) Exhibits:

Exhibit No.	Description
99.1	Press Release entitled Affyma [®] Announces Retirement Plans of Robert B. Naso, Ph.D. Executive Vice President, Research and Development .

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

AFFYMAX, INC.

Dated: November 2, 2007

By: /s/ Grace U. Shin
Grace U. Shin
Vice President, Legal Affairs and
Corporate Counsel

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release entitled Affyma [®] Announces Retirement Plans of Robert B. Naso, Ph.D. Executive Vice President, Research and Development .